Clinical Setting
Activomics
clinical laboratory
clinical utility
debilitating disease
clinical diagnostic laboratories
Inflammatory Bowel Disease
novel Activomic biomarker
order
targeted therapy of IBD
global diagnostics market
detailed business plan
comprehensive business plan
proprietary biomarker discovery tool
Activomic biomarkers
major toll
major breakthrough
concomitant heavy economic burden
patients
public health
proteins
healthcare system
unhealthy controls
disruptive technology
approach
subset
vital cell-signalling enzymes
ELISA
high accuracy
exciting milestone
funding
large patient cohorts
emphasis
enzymatic activities
introduction
MS proteomics
suffering
Better diagnosis
Screening of sera
sensitive methods
current protein-concentration
taxpayer
blood
effective serological marker
millions of sufferers
prognostics
roadmap
TACTICS
private investment
SME-phase
costs
people
Europe
sensitivity
goal
progression